Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Pancreatic Cancer Research Team |
---|---|
Information provided by: | Pancreatic Cancer Research Team |
ClinicalTrials.gov Identifier: | NCT00226005 |
The purpose of this research study is to find out if an experimental drug called PTK787/ZK222584 might be effective against advanced or metastatic pancreatic cancer.
In order for tumors to grow and spread to other parts of the body, they need to have a growing blood supply. Tumor cells have been shown to produce substances that stimulate the abnormal growth of new blood vessels that allow the tumor to grow. In adults, blood vessel cells normally divide very rapidly. It is thought that PTK787/ZK222584 may interfere with the growth of new blood vessels. A drug that interferes with the growth of new blood vessels might stop tumor growth, and possibly shrink the tumor by keeping it from receiving nutrients and oxygen supplied by the blood vessels. Since normal blood vessel cells divide very rarely, it might be possible to stop tumor growth without harming normal tissues.
Condition | Intervention | Phase |
---|---|---|
Neoplasm |
Drug: PTK787/ZK222584 |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Phase II Trial of PTK787/ZK222584 in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma Who Failed First-Line Gemcitabine Therapy. |
Estimated Enrollment: | 65 |
Study Start Date: | December 2005 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Arizona | |
University of Arizona/Arizona Cancer Center | |
Tucson, Arizona, United States, 85724 | |
Scottsdale Healthcare | |
Scottsdale, Arizona, United States, 85259 | |
United States, California | |
Tower Hematology Oncology Medical Group | |
Beverly Hills, California, United States, 90211-18500 | |
United States, Maryland | |
Sidney Kimmel Comprehensive Cancer Center/Johns Hopkins | |
Baltimore, Maryland, United States, 21231 | |
United States, Minnesota | |
Virginia Piper Cancer Institute/Abbott Northwestern Hospital | |
Minneapolis, Minnesota, United States, 55407 | |
United States, Tennessee | |
Sarah Cannon Research Institute | |
Nashville, Tennessee, United States, 37203 | |
United States, Texas | |
South Texas Oncology and Hematology | |
San Antonio, Texas, United States, 78229 |
Principal Investigator: | Tomislav Dragovich, MD, PhD | University of Arizona/Arizona Cancer Center |
Study ID Numbers: | PCRT04-001 |
Study First Received: | September 22, 2005 |
Last Updated: | April 1, 2008 |
ClinicalTrials.gov Identifier: | NCT00226005 |
Health Authority: | United States: Food and Drug Administration |
pancreas adenocarcinoma cancer metastatic advanced cancer |
Phase II growth factor VEGF angiogenesis |
Gemcitabine Adenocarcinoma Pancrelipase |
Vatalanib Neoplasms, Glandular and Epithelial Carcinoma |
Neoplasms Neoplasms by Histologic Type Molecular Mechanisms of Pharmacological Action |
Enzyme Inhibitors Protein Kinase Inhibitors Pharmacologic Actions |